CLX-0921 is investigated for use/treatment in diabetes mellitus type 2. CLX-0921 is a solid. CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the... This substance targets the protein peroxisome proliferator-activated receptor gamma.
- Mechanism
- Curator reviewed
CLX-0921 has a spectrum of activity that differs from commercially available TZDs. It also increases glycogen synthesis, an activity not typically associated with rosiglitazone or pioglitazone. Thus it appears to have a distinct spectrum of activity relative to other TZDs.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Code names
- CLX-0921
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with CLX-0921, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account